Background Coronavirus disease 2019 (Covid-19) occurs after exposure to severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the …

… s initial endpoint of at least hospitalization proved inappropriate; a problem shared by Mitja.
Mitja’s … United States has greatly expanded since our trial’s conduct in March and April 2020. …

Background WHO recommends Xpert MTB/RIF as initial diagnostic testing for tuberculous
meningitis. However, diagnosis remains difficult, with Xpert sensitivity of about 50–70% and …

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly
emerging virus causing the ongoing coronavirus disease 2019 (COVID-19) pandemic with no …

Background Identifying new antifungals for cryptococcal meningitis is a priority given the
inadequacy of current therapy. Sertraline has previously shown in vitro and in vivo activity …

Introduction Tuberculous meningitis accounts for 1–5% of tuberculosis cases. Diagnostic
delay contributes to poor outcomes. We evaluated the performance of the new Xpert MTB/RIF …

Background High-dose rifampicin may improve outcomes of tuberculous meningitis (TBM).
Little safety or pharmacokinetic (PK) data exist on high-dose rifampicin in human …

Background Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel
pathogen causing the current worldwide coronavirus disease 2019 (COVID-19) pandemic. Due …

Background Use of hydroxychloroquine in hospitalized patients with coronavirus disease
2019 (COVID-19), especially in combination with azithromycin, has raised safety concerns. …

Amphotericin B deoxycholate (AMB) has substantial toxicities. A novel encochleated
amphotericin B deoxycholate (cAMB) formulation has oral bioavailability, efficacy in an animal …